The TGFBI-associated corneal dystrophies are a group of autosomal dominant epithelial-stromal corneal disorders caused by missense mutations in the TGFBI gene encoding transforming growth factor beta induced protein (TGFBIp, also known as keratoepithelin). TGFBIp accumulates as insoluble deposits in the cornea in various forms depending on the specific mutation. The codons R124 and R555 are mutational hotspots, with clear genotype-phenotype correlations determining the subtype. Over 70 different pathogenic TGFBI mutations have been described worldwide, with the five most common (R124H, R124C, R124L, R555W, R555Q) accounting for approximately 75% of cases. There is no effective treatment to prevent, halt, or reverse TGFBIp deposition; management relies on corneal transplantation for advanced disease, though recurrence in the graft is common.
Ask a research question about TGFBI Corneal Dystrophies. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: TGFBI Corneal Dystrophies
creation_date: "2026-04-04T00:00:00Z"
updated_date: "2026-04-24T00:00:00Z"
description: >-
The TGFBI-associated corneal dystrophies are a group of autosomal dominant
epithelial-stromal corneal disorders caused by missense mutations in the
TGFBI gene encoding transforming growth factor beta induced protein (TGFBIp,
also known as keratoepithelin). TGFBIp accumulates as insoluble deposits in
the cornea in various forms depending on the specific mutation. The codons
R124 and R555 are mutational hotspots, with clear genotype-phenotype
correlations determining the subtype. Over 70 different pathogenic TGFBI
mutations have been described worldwide, with the five most common (R124H,
R124C, R124L, R555W, R555Q) accounting for approximately 75% of cases.
There is no effective treatment to prevent, halt, or reverse TGFBIp deposition;
management relies on corneal transplantation for advanced disease, though
recurrence in the graft is common.
category: Genetic
parents:
- Corneal Dystrophy
- Ophthalmological Disease
disease_term:
preferred_term: epithelial-stromal TGFBI dystrophy
term:
id: MONDO:0000764
label: epithelial-stromal TGFBI dystrophy
has_subtypes:
- name: GCD1
display_name: Granular Corneal Dystrophy Type I
description: >-
Characterized by discrete, well-demarcated, breadcrumb-like hyaline
deposits in the anterior corneal stroma. Caused by the R555W mutation.
Progressive visual impairment over decades.
subtype_term:
preferred_term: granular corneal dystrophy type I
term:
id: MONDO:0007377
label: granular corneal dystrophy type I
- name: GCD2
display_name: Granular Corneal Dystrophy Type II (Avellino)
description: >-
Characterized by mixed granular and lattice deposits in the corneal
stroma, combining features of both granular and lattice dystrophies.
Caused by the R124H mutation. Homozygotes have severe early-onset
disease. Particularly common in Korean populations.
subtype_term:
preferred_term: granular corneal dystrophy type II
term:
id: MONDO:0011855
label: granular corneal dystrophy type II
- name: LCD1
display_name: Lattice Corneal Dystrophy Type I
description: >-
Characterized by amyloid deposits forming branching lattice lines
in the corneal stroma. Caused by the R124C mutation. Recurrent
corneal erosions are common.
subtype_term:
preferred_term: lattice corneal dystrophy type I
term:
id: MONDO:0007380
label: lattice corneal dystrophy type I
- name: RBCD
display_name: Reis-Bucklers Corneal Dystrophy
description: >-
Superficial corneal dystrophy with irregular deposits at the level
of Bowman layer. Caused by the R124L mutation. Presents with
recurrent corneal erosions from early childhood.
subtype_term:
preferred_term: Reis-Bucklers corneal dystrophy
term:
id: MONDO:0012043
label: Reis-Bucklers corneal dystrophy
- name: TBCD
display_name: Thiel-Behnke Corneal Dystrophy
description: >-
Superficial corneal dystrophy with honeycomb-shaped deposits at
Bowman layer. Caused by the R555Q mutation. Clinically similar to
Reis-Bucklers but with distinct ultrastructural features.
subtype_term:
preferred_term: Thiel-Behnke corneal dystrophy
term:
id: MONDO:0011185
label: Thiel-Behnke corneal dystrophy
prevalence:
- population: Global
percentage: Rare
inheritance:
- name: Autosomal Dominant
inheritance_term:
preferred_term: Autosomal dominant inheritance
term:
id: HP:0000006
label: Autosomal dominant inheritance
pathophysiology:
- name: TGFBI Mutation and Protein Misfolding
description: >-
Missense mutations in TGFBI alter the structure of TGFBIp
(keratoepithelin), a secreted extracellular matrix protein expressed
by corneal epithelial cells. The mutant protein misfolds, disrupting
normal protein folding and stability. The severity and age of onset
depend on the specific amino acid alteration.
cell_types:
- preferred_term: Corneal epithelial cell
term:
id: CL:0000575
label: corneal epithelial cell
biological_processes:
- preferred_term: Protein folding
term:
id: GO:0006457
label: protein folding
modifier: ABNORMAL
locations:
- preferred_term: Cornea
term:
id: UBERON:0000964
label: cornea
downstream:
- target: TGFBIp Corneal Deposition
description: Misfolded TGFBIp accumulates as insoluble deposits in the corneal stroma.
evidence:
- reference: PMID:25284770
reference_title: "Clinical and genetic aspects of the TGFBI-associated corneal dystrophies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The gene product, transforming growth factor β induced protein
(TGFBIp) accumulates as insoluble deposits in various forms. The
severity, clinicopathogenic variations, age of the onset, and
location of the deposits depend on the type of amino acid
alterations in the protein.
explanation: >-
Comprehensive review establishing the mechanism of TGFBIp
deposition and genotype-phenotype correlation.
- reference: PMID:11501939
reference_title: "Corneal dystrophies in Japan."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The codons R124 and R555 of the TGFBI gene were hotspots in
Japanese patients
explanation: >-
Establishes R124 and R555 as mutational hotspots with clear
genotype-phenotype correlation.
- name: TGFBIp Corneal Deposition
description: >-
Structurally altered TGFBIp accumulates as insoluble deposits in the
corneal stroma. The specific mutation determines the type of deposit:
hyaline (granular), amyloid (lattice), or mixed (Avellino). Deposit
morphology is mutation-dependent: R555W produces hyaline deposits,
R124C produces amyloid lattice deposits, and R124H produces mixed
granular-lattice deposits.
cell_types:
- preferred_term: keratocyte
term:
id: CL:0002363
label: keratocyte
biological_processes:
- preferred_term: Extracellular matrix organization
term:
id: GO:0030198
label: extracellular matrix organization
modifier: INCREASED
locations:
- preferred_term: Corneal stroma
term:
id: UBERON:0001777
label: substantia propria of cornea
downstream:
- target: Progressive Corneal Opacification
description: Progressive accumulation of TGFBIp deposits reduces corneal transparency.
evidence:
- reference: PMID:25284770
reference_title: "Clinical and genetic aspects of the TGFBI-associated corneal dystrophies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The deposition of insoluble protein materials in the form of
extracellular deposits or intracellular cysts is pathognomic.
explanation: >-
Confirms that insoluble protein deposition in the cornea is the
pathognomonic feature of TGFBI dystrophies.
- reference: DOI:10.3341/kjo.2023.0032
reference_title: "Mini-Review: Clinical Features and Management of Granular Corneal Dystrophy Type 2"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
It is characterized by well demarcated granular shaped opacities in
central anterior stroma and as the disease progresses, extrusion of
the deposits results in ocular pain due to corneal epithelial erosion.
explanation: >-
Granular corneal dystrophy type 2 evidence localizes TGFBI-related
deposits to the anterior stroma, the keratocyte-containing corneal
stromal compartment.
- name: Progressive Corneal Opacification
description: >-
Progressive accumulation of TGFBIp deposits reduces corneal
transparency and visual acuity over decades. There is no effective
treatment to prevent, halt, or reverse TGFBIp deposition.
locations:
- preferred_term: Cornea
term:
id: UBERON:0000964
label: cornea
evidence:
- reference: PMID:25284770
reference_title: "Clinical and genetic aspects of the TGFBI-associated corneal dystrophies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
There is no effective treatment to prevent, halt, or reverse the
deposition of TGFBIp.
explanation: >-
Confirms lack of disease-modifying treatments and progressive
nature of corneal opacification.
histopathology:
- name: Insoluble TGFBIp corneal deposits
description: >-
TGFBI-associated corneal dystrophies show pathognomonic insoluble protein
deposits in corneal tissue, with deposit form and location varying by
genotype and clinicopathologic subtype.
frequency: VERY_FREQUENT
diagnostic: true
evidence:
- reference: PMID:25284770
reference_title: "Clinical and genetic aspects of the TGFBI-associated corneal dystrophies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The deposition of insoluble protein materials in the form of
extracellular deposits or intracellular cysts is pathognomic.
explanation: >-
Establishes insoluble corneal protein deposits as the defining
histopathologic finding in TGFBI-associated corneal dystrophies.
- name: Granular corneal dystrophy type 2 anterior stromal deposits
description: >-
GCD2 shows well-demarcated granular opacities in the central anterior
corneal stroma; deposit extrusion can cause epithelial erosion and pain.
subtype: GCD2
evidence:
- reference: DOI:10.3341/kjo.2023.0032
reference_title: "Mini-Review: Clinical Features and Management of Granular Corneal Dystrophy Type 2"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
It is characterized by well demarcated granular shaped opacities in
central anterior stroma and as the disease progresses, extrusion of
the deposits results in ocular pain due to corneal epithelial erosion.
explanation: >-
Provides subtype-specific corneal stromal deposit morphology and its
relationship to epithelial erosion in GCD2.
- name: Granular corneal dystrophy type 1 Masson-positive deposits
description: >-
GCD1 is associated with R555W TGFBI variants and shows granular/hyaline
stromal deposits that are highlighted by Masson trichrome staining.
subtype: GCD1
evidence:
- reference: PMID:22355247
reference_title: "Phenotype-genotype correlations in patients with TGFBI-linked corneal dystrophies in Taiwan."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The most common mutations in Taiwan were R124H in GCD type 2 and
R555W in GCD type 1.
explanation: >-
Supports the genotype-subtype assignment for the GCD1 histopathology
entry.
- reference: PMID:20697279
reference_title: "Granular and lattice deposits in corneal dystrophy caused by R124C mutation of TGFBIp."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
granular deposits stained with Masson trichrome and lattice deposits
stained with ThT and Congo red showed birefringence and dichroism as
expected.
explanation: >-
Supports Masson trichrome staining as a marker of granular/hyaline
corneal deposits.
- name: Lattice corneal dystrophy type 1 amyloid deposits
description: >-
LCD1 is associated with R124C TGFBI variants and shows stromal amyloid
deposits with lattice morphology; amyloid deposits are detected by Congo
red or related amyloid stains.
subtype: LCD1
evidence:
- reference: PMID:38359414
reference_title: "IC3D Classification of Corneal Dystrophies-Edition 3."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Classic lattice corneal dystrophy (LCD) results from TGFBI R124C
mutation. The LCD variant group has over 80 dystrophies with
non-R124C TGFBI mutations, amyloid deposition, and often similar
phenotypes to classic LCD.
explanation: >-
IC3D supports the R124C association and amyloid-deposit pattern for
classic lattice corneal dystrophy.
- reference: PMID:20697279
reference_title: "Granular and lattice deposits in corneal dystrophy caused by R124C mutation of TGFBIp."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In control LCD sections, stromal deposits were stained with ThT but
not with trichrome, confirming lack of granular deposits.
explanation: >-
Supports amyloid-type staining in lattice corneal dystrophy and
distinguishes LCD deposits from granular Masson-positive deposits.
phenotypes:
- category: Ophthalmologic
name: Corneal Opacity
description: >-
Progressive corneal opacification due to accumulation of TGFBIp
deposits in the corneal stroma. The pattern and morphology of
deposits varies by subtype.
phenotype_term:
preferred_term: Corneal opacity
term:
id: HP:0007957
label: Corneal opacity
evidence:
- reference: PMID:25284770
reference_title: "Clinical and genetic aspects of the TGFBI-associated corneal dystrophies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Corneal dystrophies are a group of inherited disorders localized
to various layers of the cornea that affect corneal transparency
and visual acuity.
explanation: >-
Corneal opacity is the defining feature of all TGFBI dystrophies.
- category: Ophthalmologic
name: Corneal Dystrophy
description: >-
Bilateral symmetric corneal dystrophy with characteristic deposit
patterns visible on slit-lamp examination.
phenotype_term:
preferred_term: Corneal dystrophy
term:
id: HP:0001131
label: Corneal dystrophy
- category: Ophthalmologic
name: Recurrent Corneal Erosions
description: >-
Recurrent painful epithelial erosions, particularly common in
lattice, Reis-Bucklers, and Thiel-Behnke subtypes.
phenotype_term:
preferred_term: Recurrent corneal erosions
term:
id: HP:0000495
label: Recurrent corneal erosions
evidence:
- reference: DOI:10.3341/kjo.2023.0032
reference_title: "Mini-Review: Clinical Features and Management of Granular Corneal Dystrophy Type 2"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
extrusion of the deposits results in ocular pain due to corneal
epithelial erosion.
explanation: >-
Supports epithelial erosion as a clinical consequence of progressive
TGFBI-related corneal deposits in GCD2.
- category: Ophthalmologic
name: Reduced Visual Acuity
description: >-
Progressive reduction in visual acuity as deposits accumulate.
Severity and age of onset depend on the specific mutation. Homozygous
GCD2 (R124H) patients have severe early-onset visual loss.
phenotype_term:
preferred_term: Reduced visual acuity
term:
id: HP:0007663
label: Reduced visual acuity
evidence:
- reference: PMID:25284770
reference_title: "Clinical and genetic aspects of the TGFBI-associated corneal dystrophies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Corneal dystrophies are a group of inherited disorders localized
to various layers of the cornea that affect corneal transparency
and visual acuity.
explanation: >-
Establishes visual acuity impairment as a clinical effect of inherited
corneal dystrophies including TGFBI-associated forms.
- reference: DOI:10.3341/kjo.2023.0032
reference_title: "Mini-Review: Clinical Features and Management of Granular Corneal Dystrophy Type 2"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Also, diffuse corneal haze which appears late, causes decrease in
visual acuity.
explanation: >-
Directly supports reduced visual acuity as a consequence of late
diffuse corneal haze in GCD2.
- category: Ophthalmologic
name: Lattice Corneal Dystrophy Pattern
subtype: LCD1
description: >-
Branching lattice lines of amyloid in the corneal stroma,
pathognomonic for lattice corneal dystrophy type I.
phenotype_term:
preferred_term: Lattice corneal dystrophy
term:
id: HP:0001149
label: Lattice corneal dystrophy
- category: Ophthalmologic
name: Granular Corneal Dystrophy Pattern
subtype: GCD1
description: >-
Discrete breadcrumb-like hyaline deposits in the anterior
corneal stroma, characteristic of granular CD type I.
phenotype_term:
preferred_term: Granular corneal dystrophy
term:
id: HP:0007802
label: Granular corneal dystrophy
genetic:
- name: TGFBI Missense Mutations
association: Pathogenic Variants
gene_term:
preferred_term: TGFBI
term:
id: hgnc:11771
label: TGFBI
inheritance:
- name: Autosomal Dominant
inheritance_term:
preferred_term: Autosomal dominant inheritance
term:
id: HP:0000006
label: Autosomal dominant inheritance
features: >-
Missense mutations at hotspot codons R124 and R555 account for most
cases. Over 70 pathogenic mutations reported. The five most common
(R124H, R124C, R124L, R555W, R555Q) account for ~75% of cases
worldwide. Clear genotype-phenotype correlations: R555W=GCD1,
R124H=GCD2, R124C=LCD1, R124L=RBCD, R555Q=TBCD.
evidence:
- reference: PMID:30760895
reference_title: "Evaluation of TGFBI corneal dystrophy and molecular diagnostic testing."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
To date, 70 different TGFBI mutations that cause
epithelial-stromal corneal dystrophies have been described.
explanation: >-
Comprehensive mutation survey establishing 70+ pathogenic TGFBI
variants.
- reference: PMID:30760895
reference_title: "Evaluation of TGFBI corneal dystrophy and molecular diagnostic testing."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
an increase to the worldwide detection rate in all populations
from 75 to 90% could be achieved by the addition of six mutations
explanation: >-
The 5 hotspot mutations account for 75% of cases; 11 mutations
cover 90%.
- reference: PMID:11501939
reference_title: "Corneal dystrophies in Japan."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
These studies showed a clear genotype/phenotype correlation
associated with the TGFBI gene.
explanation: >-
Confirms clear genotype-phenotype correlations across populations.
treatments:
- name: Corneal Transplantation
description: >-
Penetrating keratoplasty or deep anterior lamellar keratoplasty for
advanced disease with significant visual impairment. Recurrence of
deposits in the graft is common, particularly for lattice and
granular dystrophies.
treatment_term:
preferred_term: Corneal transplantation
term:
id: MAXO:0010039
label: organ transplantation
evidence:
- reference: DOI:10.3390/vision7010022
reference_title: "Management of Stromal Corneal Dystrophies; Review of the Literature with a Focus on Phototherapeutic Keratectomy and Keratoplasty"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Where there is visual reduction, treatment options may include
either phototherapeutic keratectomy (PTK) or corneal transplantation.
explanation: >-
Review explicitly identifies corneal transplantation as a treatment
option for visually significant stromal corneal dystrophies.
- reference: DOI:10.3341/kjo.2023.0032
reference_title: "Mini-Review: Clinical Features and Management of Granular Corneal Dystrophy Type 2"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
For deeper lesions, deep anterior lamellar keratoplasty can be used
as the endothelial layer is not always affected.
explanation: >-
GCD2 management review supports lamellar keratoplasty for deeper
stromal deposits.
- name: Phototherapeutic Keratectomy
description: >-
Excimer laser phototherapeutic keratectomy (PTK) can remove
superficial deposits and improve visual acuity, particularly for
Reis-Bucklers and Thiel-Behnke subtypes.
treatment_term:
preferred_term: Phototherapeutic keratectomy
term:
id: MAXO:0000004
label: surgical procedure
evidence:
- reference: DOI:10.3390/vision7010022
reference_title: "Management of Stromal Corneal Dystrophies; Review of the Literature with a Focus on Phototherapeutic Keratectomy and Keratoplasty"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Due to the anterior location of the deposits in Reis-Bücklers and
Thiel–Behnke dystrophies, PTK is considered the treatment of choice.
explanation: >-
Review directly supports PTK for anterior TGFBI-associated
epithelial-stromal corneal dystrophy deposits.
- reference: DOI:10.3341/kjo.2023.0032
reference_title: "Mini-Review: Clinical Features and Management of Granular Corneal Dystrophy Type 2"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Phototherapeutic keratectomy removes anterior opacities and is
advantageous in terms of its applicability and repeatability.
explanation: >-
GCD2 review supports PTK for anterior corneal opacities.
- name: Genetic Counseling
description: >-
Genetic counseling regarding autosomal dominant inheritance with
50% recurrence risk. Genetic testing is recommended before
refractive surgery (LASIK) as TGFBI mutations can cause severe
corneal haze post-LASIK.
treatment_term:
preferred_term: Genetic counseling
term:
id: MAXO:0000079
label: genetic counseling
evidence:
- reference: PMID:30760895
reference_title: "Evaluation of TGFBI corneal dystrophy and molecular diagnostic testing."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Therefore, it is our opinion that genetic screening for these late
onset, heterozygous mutations should be performed before refractive
surgeries
explanation: >-
Directly supports genetic screening and counseling before refractive
surgery in people at risk for late-onset heterozygous TGFBI
mutations.
datasets:
Question: You are an expert researcher providing comprehensive, well-cited information.
Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies
Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.
Please provide a comprehensive research report on TGFBI Corneal Dystrophies covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.
For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.
Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed
Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Search first: CTD, PubMed, PheGenI, GxE databases
Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC
For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype
Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser
Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Search first: CDC databases, WHO, PubMed, NHANES
Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON
Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Search first: PubMed, Gene Ontology, Reactome
Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types
Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Search first: OMIM, Orphanet, HPO, PubMed
Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.
Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Search first: NSGC resources, ACMG guidelines, GeneReviews
Search first: Clinical guidelines, FDA approvals, PubMed
Search first: NCBI Taxonomy
Search first: VBO (Vertebrate Breed Ontology)
Search first: NCBI Gene
Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease
This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details
TGFBI corneal dystrophies (also termed epithelial–stromal TGFBI dystrophies in IC3D nomenclature) are autosomal-dominant, genotype-driven corneal deposition disorders caused by pathogenic variants in TGFBI (5q31) that lead to progressive accumulation of abnormal extracellular deposits (hyaline and/or amyloid) within corneal layers, resulting in recurrent erosions, stromal opacification, and vision loss. Mutational “hotspots” at Arg124 and Arg555 account for many classic subtype presentations (e.g., p.Arg124His in granular corneal dystrophy type 2/Avellino, p.Arg555Trp in granular corneal dystrophy type 1). Recurrence after corneal procedures is common, so management emphasizes conservative treatment for erosions and staged surgical approaches (PTK → lamellar keratoplasty → penetrating keratoplasty for deep disease) while avoiding refractive surgery in susceptible individuals. (kheir2019mutationupdatetgfbi pages 1-2, chang2023minireviewclinicalfeatures pages 1-3, chang2023minireviewclinicalfeatures pages 3-5, ashena2023managementofstromal pages 8-9)
Corneal dystrophies are inherited disorders characterized by progressive deposition of abnormal material in the cornea. (zhu2023variantlandscapeof pages 1-2)
TGFBI corneal dystrophies are a genetically-defined subset (“epithelial–stromal TGFBI dystrophies”) in the IC3D classification and include Reis–Bücklers corneal dystrophy (RBCD), Thiel–Behnke corneal dystrophy (TBCD), lattice corneal dystrophies (LCDs), granular corneal dystrophy type 1 (GCD1), and granular corneal dystrophy type 2 (GCD2/Avellino). (mdUnknownyearnomenclatureréviséedu pages 11-15, mdUnknownyearnomenclatureréviséedu pages 8-11, sciriha2024geneticvariantsina pages 58-61)
IC3D (3rd edition) group: Epithelial–stromal TGFBI dystrophies. (mdUnknownyearnomenclatureréviséedu pages 11-15, mdUnknownyearnomenclatureréviséedu pages 8-11)
OMIM (MIM) IDs reported in IC3D-derived table text: - RBCD: MIM #608470 (sciriha2024geneticvariantsina pages 58-61) - TBCD: MIM #602082 (sciriha2024geneticvariantsina pages 58-61) - LCD1: MIM #122200 (sciriha2024geneticvariantsina pages 58-61) - GCD1: MIM #121900 (sciriha2024geneticvariantsina pages 58-61) - GCD2: MIM #607541 (sciriha2024geneticvariantsina pages 58-61)
MONDO / Orphanet / MeSH / ICD-10/ICD-11: Not retrieved from the available tool-accessible sources in this run; additional targeted retrieval from OMIM/Orphanet/NCBI MeSH/WHO ICD would be required for authoritative IDs. (mdUnknownyearnomenclatureréviséedu pages 11-15, mdUnknownyearnomenclatureréviséedu pages 8-11)
TGFBI gene/protein synonyms and related terms include BIGH3, βig-h3, keratoepithelin, TGFBIp, and RGD-CAP. (kheir2019mutationupdatetgfbi pages 1-2, kheir2019mutationupdatetgfbi pages 2-3)
Key disease synonym highlighted in multiple sources: - GCD2 is also called Avellino corneal dystrophy. (ashena2023managementofstromal pages 13-15, sciriha2024geneticvariantsinb pages 78-82)
Primary cause: germline pathogenic variants in TGFBI (chromosome 5q31) encoding an extracellular matrix (ECM) adhesion protein (TGFBIp) that accumulates in corneal deposits. (sciriha2025transcriptomeanalysisof pages 1-3, kheir2019mutationupdatetgfbi pages 2-3)
Genetic risk factors (causal variants): - Pathogenic/likely pathogenic TGFBI variants are enriched at amino acids Arg124 and Arg555 (“hotspots”), and many phenotypes have strong genotype–phenotype correlations. (kheir2019mutationupdatetgfbi pages 1-2, kheir2019mutationupdatetgfbi pages 2-3) - Examples of classic genotype–phenotype links include: - p.Arg555Trp → GCD1; p.Arg555Gln → TBCD; p.Arg124Cys → LCD1; p.Arg124His → GCD2. (kheir2019mutationupdatetgfbi pages 1-2)
Iatrogenic/surgical risk: corneal laser refractive procedures can exacerbate GCD2 with rapid worsening and severe visual deterioration; this is repeatedly cited and used as a rationale for genetic screening in refractive surgery candidates. (chang2023minireviewclinicalfeatures pages 1-3, chang2023minireviewclinicalfeatures pages 3-5, zeng2017tgfbigenemutation pages 1-2)
No specific genetic or environmental protective factors were identified in the retrieved evidence. (kheir2019mutationupdatetgfbi pages 1-2)
The clearest gene–environment interaction supported here is surgical trauma (e.g., LASIK/PRK/LASEK/SMILE) interacting with TGFBI mutations (notably p.Arg124His) to accelerate deposit formation and clinical progression. (chang2023minireviewclinicalfeatures pages 1-3, chang2023minireviewclinicalfeatures pages 3-5)
Because IC3D emphasizes overlap across TGFBI phenotypes, the following are recurring features:
A. Corneal stromal opacities / deposits - Clinical: granular/linear (lattice-like) stromal opacities; central predominance. (chang2023minireviewclinicalfeatures pages 1-3, chang2023minireviewclinicalfeatures pages 3-5, sciriha2024geneticvariantsinb pages 78-82) - Suggested HPO: Corneal opacity (HP:0007957); Corneal stromal haze (often mapped under corneal opacity)
B. Recurrent corneal epithelial erosion with pain - Particularly highlighted in GCD2 and RBCD-like superficial phenotypes. (chang2023minireviewclinicalfeatures pages 1-3, chang2023minireviewclinicalfeatures pages 3-5, sciriha2024geneticvariantsina pages 78-82) - Suggested HPO: Recurrent corneal erosion (HP:0000557); Eye pain (HP:0004444)
C. Decreased visual acuity / progressive visual impairment - Reported as deposits progress and haze develops. (chang2023minireviewclinicalfeatures pages 1-3, chang2023minireviewclinicalfeatures pages 3-5) - Suggested HPO: Reduced visual acuity (HP:0007663)
D. Genotype-specific histopathologic patterns - GCD2: combined hyaline granular + amyloid linear deposits; hyaline stains with Masson trichrome; amyloid with Congo red; TEM rod-shaped deposits in anterior stroma. (chang2023minireviewclinicalfeatures pages 3-5, ashena2023managementofstromal pages 13-15, sciriha2024geneticvariantsinb pages 78-82) - LCD: branching/interdigitating linear amyloid opacities; Congo red positive. (sciriha2024geneticvariantsina pages 78-82, sciriha2024geneticvariantsinb pages 78-82)
A subtype-specific frequency estimate is available for GCD2 within regions: - In Korea/Japan, GCD2 is reported as 72–91% of TGFBI dystrophies; 67% in China, 36% in the U.S., and 3% in Poland. (chang2023minireviewclinicalfeatures pages 1-3)
Direct QoL instruments (EQ-5D/SF-36) were not found in the retrieved evidence; however, the combination of painful erosions and progressive vision loss implies substantial functional impairment. (chang2023minireviewclinicalfeatures pages 1-3, chang2023minireviewclinicalfeatures pages 3-5)
TGFBI (transforming growth factor beta induced), locus 5q31; a 17-exon gene encoding a secreted ~683-aa ECM protein. (kheir2019mutationupdatetgfbi pages 2-3, sciriha2024geneticvariantsina pages 58-61)
Representative genotype–phenotype associations (examples): - p.Arg124His (R124H) → GCD2 / Avellino (kheir2019mutationupdatetgfbi pages 1-2, chang2023minireviewclinicalfeatures pages 1-3) - p.Arg555Trp (R555W) → GCD1 (kheir2019mutationupdatetgfbi pages 1-2, sciriha2024geneticvariantsinb pages 78-82) - p.Arg124Cys (R124C) → LCD1 (kheir2019mutationupdatetgfbi pages 1-2, sciriha2024geneticvariantsinb pages 78-82) - p.Arg555Gln (R555Q) → TBCD (kheir2019mutationupdatetgfbi pages 1-2)
TGFBIp is a secreted ECM protein with an N-terminal EMI domain, four FAS1 repeats, and a C-terminal RGD integrin-binding motif, and it binds collagens and contributes to corneal ECM architecture. (sciriha2025transcriptomeanalysisof pages 1-3, kheir2019mutationupdatetgfbi pages 2-3)
Mechanistic hypotheses summarized include altered protein–protein interactions, misfolding/solubility changes, oxidative stress susceptibility, and impaired autophagy, with a cornea-specific extracellular milieu contributing to deposit formation. (sciriha2025transcriptomeanalysisof pages 1-3)
Not identified in the retrieved evidence for this run. (kheir2019mutationupdatetgfbi pages 1-2)
No strong evidence for environmental toxins, lifestyle factors, or infectious triggers was retrieved. The clearest non-genetic contributor is corneal surgery/trauma (e.g., refractive surgery) accelerating disease expression in mutation carriers. (chang2023minireviewclinicalfeatures pages 1-3, chang2023minireviewclinicalfeatures pages 3-5)
1) Pathogenic TGFBI variant produces an abnormal TGFBIp (ECM adhesion protein). (kheir2019mutationupdatetgfbi pages 1-2, kheir2019mutationupdatetgfbi pages 2-3) 2) Abnormal TGFBIp undergoes aberrant extracellular accumulation/aggregation in the cornea (often detectable by anti-TGFBI immunoreactivity). (kheir2019mutationupdatetgfbi pages 2-3) 3) Deposits can be hyaline (granular; Masson trichrome red) and/or amyloid (lattice; Congo red), depending on genotype/phenotype. (sciriha2024geneticvariantsina pages 78-82, sciriha2024geneticvariantsinb pages 78-82) 4) Deposits disrupt corneal transparency and can protrude toward the epithelium, leading to recurrent erosions, pain, and progressive visual impairment. (chang2023minireviewclinicalfeatures pages 1-3, chang2023minireviewclinicalfeatures pages 3-5)
Transcriptomic analysis of TGFBI knockdown in human corneal epithelial cells reported enrichment of pathways including SMAD, JAK-STAT, and PI3K-Akt (as pathway-level signals potentially tied to epithelial homeostasis and scarring/angiogenesis programs). (sciriha2025transcriptomeanalysisof pages 1-3)
Suggested GO Biological Process terms (high-level, consistent with evidence): - extracellular matrix organization - cell adhesion - integrin-mediated signaling pathway - autophagy (as a hypothesized mechanism) (sciriha2025transcriptomeanalysisof pages 1-3)
Evidence supports major relevance of corneal epithelial cells (major transcription source) and keratocytes (stromal cells) as contributors to ECM/deposit dynamics. (sciriha2025transcriptomeanalysisof pages 1-3, chang2023minireviewclinicalfeatures pages 3-5)
Suggested Cell Ontology (CL) terms: - Corneal epithelial cell - Keratocyte
Primary affected organ: cornea. (zhu2023variantlandscapeof pages 1-2)
Localization includes epithelial–stromal involvement and often multi-layer involvement under IC3D’s genetics-based grouping. (sciriha2024geneticvariantsina pages 58-61, mdUnknownyearnomenclatureréviséedu pages 8-11)
Suggested UBERON terms: - cornea (UBERON:0000964) - corneal stroma (UBERON:0001775) - corneal epithelium (UBERON:0001774)
No subcellular compartment-specific pathology (e.g., ER/lysosome) was directly established in retrieved evidence; impaired autophagy is discussed as a hypothesis. (sciriha2025transcriptomeanalysisof pages 1-3)
Most TGFBI dystrophies are autosomal dominant. (kheir2019mutationupdatetgfbi pages 1-2, sciriha2024geneticvariantsina pages 58-61)
Large Korean population genetic screening (129,933 individuals; July 2021–Aug 2024): - Allele frequencies detected: R124H 0.10%, P501T 0.58%, R555W 0.001%. (cho2025geneticepidemiologyof pages 1-2) - Estimated prevalence (per 100,000): GCD2 203.9, LCD variant 1,160.3, GCD1 2.3; combined epithelial–stromal TGFBI dystrophies 1,365.2 per 100,000. (cho2025geneticepidemiologyof pages 1-2)
GCD2 prevalence estimate in Korea (review): about 11.5 per 10,000. (chang2023minireviewclinicalfeatures pages 1-3)
Population differences in subtype proportions (e.g., high prevalence in East Asia) are emphasized for GCD2. (chang2023minireviewclinicalfeatures pages 1-3)
Diagnosis is based on slit-lamp findings of characteristic deposits/opacities and clinical history (recurrent erosions, visual decline), with genotype confirmation recommended due to phenotypic overlap in IC3D-classified TGFBI dystrophies. (mdUnknownyearnomenclatureréviséedu pages 11-15, chang2023minireviewclinicalfeatures pages 3-5)
Evidence supports broad use of NGS/exome sequencing (with Sanger confirmation) in corneal dystrophy cohorts and targeted genotyping for known TGFBI hotspots, including screening in refractive surgery settings. (zhu2023variantlandscapeof pages 1-2, zeng2017tgfbigenemutation pages 1-2, cho2025geneticepidemiologyof pages 1-2)
In Eastern China, a pilot study using a commercial “Avellino gene test kit” detected heterozygous TGFBI mutations in 36/42 subjects; among 24 typical granular corneal dystrophy patients, mutation distribution included R124H 37.5%, R555Q 16.7%, R124L 25.0%, R555W 20.8%, and R124C 0%. The mutation detection rate was 69.2% among relatives with no corneal signs but positive family history. (zeng2017tgfbigenemutation pages 1-2)
Not systematically extracted from the retrieved texts; however, IC3D emphasizes that genotype can overturn phenotype-based misclassification due to overlap. (mdUnknownyearnomenclatureréviséedu pages 11-15)
A multicenter observational ClinicalTrials.gov study aimed to determine prevalence of five TGFBI dystrophies in refractive surgery candidates using buccal swab PCR genotyping. (NCT02746055 chunk 1) - ClinicalTrials.gov ID: NCT02746055 - Start: April 2016; estimated primary completion Dec 2016; estimated completion Apr 2017; first posted Apr 21, 2016. (NCT02746055 chunk 1) - URL (standard): https://clinicaltrials.gov/study/NCT02746055 (NCT02746055 chunk 1)
Suggested MAXO terms: - Genetic screening - Genetic counseling
For GCD2-associated erosions, conservative measures include artificial tears, topical antibiotics, and bandage contact lenses. (chang2023minireviewclinicalfeatures pages 1-3)
Suggested MAXO: - Lubricant therapy - Topical antibiotic therapy - Therapeutic contact lens fitting
PTK is widely used for anterior deposits in stromal TGFBI dystrophies and is valued for repeatability and for delaying keratoplasty, but recurrence is common. (ashena2023managementofstromal pages 1-2, ashena2023managementofstromal pages 21-22)
Quantitative PTK outcomes: - Long-term pedigree study (R124L): mean follow-up 19.6 ± 1.78 years; multiple PTKs per eye (2–4); after each PTK, “effective visual acuity” maintained 3.60 ± 1.12 years before significant recurrence; satisfaction 8.6 ± 0.89. (zeng2019multiplephototherapeutickeratectomy pages 1-3) - Granular dystrophy series summarized in review: vision improved in 79% with 20% recurrence over mean follow-up 3 ± 2.7 years; other series show ~23% significant recurrence at ~40 months; mean time to significant recurrence 23.7 ± 11.2 months in one cohort. (ashena2023managementofstromal pages 8-9) - Avellino/GCD2: PTK recurrence can be rapid (reported 7–9 months), and genotype dependent (homozygotes vs heterozygotes recurrence-free interval 9.5 ± 3.1 vs 38.4 ± 6.2 months, p < 0.001). (ashena2023managementofstromal pages 13-15)
Technique considerations: PTK is less invasive than transplantation; PTK uses 193 nm excimer light and ablates ~0.25 µm tissue per pulse/step as described in a management review. (ashena2023managementofstromal pages 1-2)
Suggested MAXO: - Phototherapeutic keratectomy
For deeper stromal disease or repeated recurrences, surgical options include ALK, DALK, or PK, with DALK often preferred when endothelium is spared to reduce rejection risk. (chang2023minireviewclinicalfeatures pages 3-5, ashena2023managementofstromal pages 19-21)
Recurrence after keratoplasty (selected data): - Avellino: deposits can recur in grafts within 12–24 months, often at suture tracts or graft–host interfaces; a DALK recurrence was reported at 13 months in one case. (ashena2023managementofstromal pages 13-15) - Granular dystrophy: DALK recurrence has been reported as 43% at mean 38.4 ± 18.6 months in one series; recurrence is associated with residual host stroma/keratocytes and may be mitigated by Descemet-baring techniques, with trade-offs in perforation risk. (ashena2023managementofstromal pages 11-12)
Suggested MAXO: - Deep anterior lamellar keratoplasty - Penetrating keratoplasty
Multiple sources emphasize that refractive laser procedures can exacerbate GCD2; therefore genetic screening can be used to prevent iatrogenic harm in mutation carriers. (chang2023minireviewclinicalfeatures pages 1-3, chang2023minireviewclinicalfeatures pages 3-5, NCT02746055 chunk 1)
Emerging strategies discussed in recent clinical reviews include pharmacologic reduction of TGFBI and gene-based approaches (siRNA/shRNA/CRISPR), but these are not established clinical treatments in the retrieved evidence set. (chang2023minireviewclinicalfeatures pages 5-6, sciriha2025transcriptomeanalysisof pages 1-3)
Primary prevention is not currently established (genetic disease), but secondary prevention is feasible: - Preoperative genetic screening in refractive surgery candidates to avoid surgery-triggered exacerbation (implemented in observational prevalence screening programs). (NCT02746055 chunk 1, zeng2017tgfbigenemutation pages 1-2)
Suggested MAXO: - Genetic counseling - Cascade genetic testing
No naturally occurring non-human species evidence was retrieved in this run. (kheir2019mutationupdatetgfbi pages 1-2)
No model-organism details were retrieved in this run; additional retrieval focused on TGFBI knock-in/CRISPR animal models would be required. (sciriha2025transcriptomeanalysisof pages 1-3)
The following table compiles subtype-level features, variants, deposit types, and treatment/recurrence notes using only retrieved evidence.
| Disease/subtype (synonyms) | Typical TGFBI hotspot variant(s) | Deposit type / histopathology | Typical onset / clinical hallmarks | Common procedures | Recurrence notes |
|---|---|---|---|---|---|
| Reis–Bücklers corneal dystrophy (RBCD; superficial GCD; Bowman's layer type I; historically linked to GCD3/"true" Reis–Bücklers in older literature) | p.Arg124Leu (R124L) (sciriha2024geneticvariantsina pages 58-61, sciriha2024geneticvariantsina pages 78-82, sciriha2024geneticvariantsinb pages 78-82) | Superficial/subepithelial deposits; histochemistry described as similar to GCD1 (hyaline-type), with early recurrent epithelial erosions; deep stroma/endothelium spared (sciriha2024geneticvariantsina pages 78-82, sciriha2024geneticvariantsinb pages 78-82) | Early recurrent painful epithelial erosions; diffuse gray-white sand-like superficial deposits; epithelial/subepithelial localization (sciriha2024geneticvariantsina pages 78-82, sciriha2024geneticvariantsinb pages 78-82) | PTK first-line for anterior disease; FLK if PTK not feasible; keratoplasty for deeper/advanced disease (ashena2023managementofstromal pages 1-2, ashena2023managementofstromal pages 19-21, ashena2023managementofstromal pages 5-7) | For Bowman's/anterior TGFBI dystrophies, PTK is preferred because deposits are superficial. Quantitative RBCD-specific recurrence intervals were not provided in the evidence snippets reviewed (ashena2023managementofstromal pages 1-2, ashena2023managementofstromal pages 19-21, ashena2023managementofstromal pages 5-7) |
| Thiel–Behnke corneal dystrophy (TBCD) | p.Arg555Gln (R555Q) (kheir2019mutationupdatetgfbi pages 1-2, sciriha2024geneticvariantsina pages 58-61) | Not detailed in the provided IC3D snippets beyond TGFBI epithelial–stromal classification; clinically grouped with anterior/Bowman-layer TGFBI dystrophies (sciriha2024geneticvariantsina pages 58-61, mdUnknownyearnomenclatureréviséedu pages 11-15, mdUnknownyearnomenclatureréviséedu pages 8-11) | Anterior/superficial opacity pattern within the Bowman/anterior stromal group; managed similarly to other superficial TGFBI dystrophies (ashena2023managementofstromal pages 1-2, ashena2023managementofstromal pages 5-7) | PTK first-line when opacity is not deeper than ~1/3 corneal thickness; FLK or keratoplasty if PTK unsuitable (ashena2023managementofstromal pages 1-2, ashena2023managementofstromal pages 5-7) | Quantitative PTK data available: simple recurrence 100% over long follow-up (~9.7 years) in one series; 50% (5/10 eyes) recurred within 12 months in another; one report noted recurrence in 16.7% after prior keratoplasty (ashena2023managementofstromal pages 5-7) |
| Lattice corneal dystrophy type 1 / LCD variants (classic LCD, LCD1) | p.Arg124Cys (R124C); other variant examples include p.Ala546Asp, p.Pro551Gln (kheir2019mutationupdatetgfbi pages 1-2, sciriha2024geneticvariantsina pages 78-82, sciriha2024geneticvariantsin pages 78-82, sciriha2024geneticvariantsinb pages 78-82) | Amyloid deposits with central branching/interdigitating linear opacities; amyloid stains with Congo red; reduced corneal sensation may occur (sciriha2024geneticvariantsina pages 78-82, sciriha2024geneticvariantsin pages 78-82, sciriha2024geneticvariantsinb pages 78-82) | Progressive visual loss, recurrent erosions, central branching lattice lines/amyloid opacities (sciriha2024geneticvariantsina pages 78-82, sciriha2024geneticvariantsin pages 78-82, sciriha2024geneticvariantsinb pages 78-82) | PTK recommended initially; repeat PTK can delay keratoplasty; DALK preferred over PK when transplant needed, with careful AS-OCT and Descemet-baring technique (ashena2023managementofstromal pages 21-22, ashena2023managementofstromal pages 19-21, ashena2023managementofstromal pages 5-7) | PTK recurrence is common but often slow: one series reported 30.1% recurrence with median time ~96 months; repeat PTK is often feasible before keratoplasty (ashena2023managementofstromal pages 21-22, ashena2023managementofstromal pages 5-7) |
| Granular corneal dystrophy type 1 (GCD1) | p.Arg555Trp (R555W) (kheir2019mutationupdatetgfbi pages 1-2, sciriha2024geneticvariantsina pages 58-61, sciriha2024geneticvariantsina pages 78-82, sciriha2024geneticvariantsinb pages 78-82) | Hyaline deposits; Masson trichrome red staining used for hyaline material (contrasted with amyloid/Congo red) (sciriha2024geneticvariantsina pages 78-82, sciriha2024geneticvariantsinb pages 78-82) | Granular stromal opacities; homozygous disease reported as more severe with earlier graft recurrence (sciriha2024geneticvariantsina pages 78-82, sciriha2024geneticvariantsinb pages 78-82) | PTK for anterior stromal lesions; repeat PTK if corneal thickness permits; DALK/ALK for less-deep disease; PK for deep/pre-Descemet involvement (ashena2023managementofstromal pages 21-22, ashena2023managementofstromal pages 8-9, ashena2023managementofstromal pages 13-15, ashena2023managementofstromal pages 11-12) | Quantitative GCD data from mixed granular series: 79% visual improvement with 20% recurrence at mean 3 ± 2.7 years; ~23% significant recurrence at ~40 months in another series; mean time to significant recurrence 23.7 ± 11.2 months in one cohort. DALK recurrence reported as 43% at mean 38.4 ± 18.6 months in one series (ashena2023managementofstromal pages 8-9, ashena2023managementofstromal pages 11-12) |
| Granular corneal dystrophy type 2 (GCD2; Avellino corneal dystrophy) | p.Arg124His (R124H) (kheir2019mutationupdatetgfbi pages 1-2, chang2023minireviewclinicalfeatures pages 1-3, ashena2023managementofstromal pages 13-15, sciriha2024geneticvariantsina pages 58-61, sciriha2024geneticvariantsina pages 78-82, sciriha2024geneticvariantsinb pages 78-82) | Mixed hyaline granular + amyloid lattice-like deposits; hyaline stains with Masson trichrome and amyloid with Congo red; rod-shaped electron-dense/anterior stromal deposits described (chang2023minireviewclinicalfeatures pages 3-5, ashena2023managementofstromal pages 13-15, sciriha2024geneticvariantsina pages 78-82, sciriha2024geneticvariantsinb pages 78-82) | Often first–second decade (heterozygotes may present in teens/young adulthood; homozygotes can present as early as age 3); central superficial white dots progressing to ring/stellate granular deposits, later deeper linear lattice-like opacities, stromal haze, painful epithelial erosions; refractive surgery can markedly exacerbate disease (chang2023minireviewclinicalfeatures pages 1-3, chang2023minireviewclinicalfeatures pages 3-5, chang2023minireviewclinicalfeatures pages 6-8, ashena2023managementofstromal pages 13-15, sciriha2024geneticvariantsinb pages 78-82) | Conservative therapy for erosions (artificial tears, antibiotics, bandage contact lens); PTK for anterior deposits; DALK/ALK for deeper disease; PK for deep or pre-Descemet involvement (chang2023minireviewclinicalfeatures pages 1-3, chang2023minireviewclinicalfeatures pages 3-5, ashena2023managementofstromal pages 13-15) | PTK recurrence is often early and genotype-dependent: recurrence intervals 7–9 months reported; homozygous vs heterozygous recurrence-free interval 9.5 ± 3.1 vs 38.4 ± 6.2 months (p < 0.001); deposits may recur within 18 months after first PTK and within 3 months after repeat PTK. After keratoplasty, graft recurrence may begin within 12–24 months; recurrence after DALK reported at 13 months in one case (chang2023minireviewclinicalfeatures pages 3-5, chang2023minireviewclinicalfeatures pages 5-6, ashena2023managementofstromal pages 13-15) |
Table: This table summarizes the major IC3D epithelial–stromal TGFBI corneal dystrophies, their typical hotspot variants, pathology, clinical presentation, and current procedure/recurrence patterns supported by the retrieved evidence. It is useful as a compact subtype-oriented reference for phenotype interpretation and management planning.
1) Genetics-driven classification and variant interpretation: Recent literature-scale analyses emphasize TGFBI’s disproportionate contribution to monogenic corneal dystrophies and the need to avoid variant misinterpretation (e.g., p.Pro501Thr). (zhu2023variantlandscapeof pages 1-2) 2) Procedure recurrence remains a dominant clinical challenge: 2023 management syntheses highlight that PTK is valuable but recurrence is common and genotype dependent (especially Avellino/GCD2). (ashena2023managementofstromal pages 13-15, ashena2023managementofstromal pages 8-9) 3) Growing emphasis on screening in refractive surgery: Clinical screening initiatives and cohort mutation studies explicitly connect TGFBI genotyping to refractive safety decisions. (NCT02746055 chunk 1, zeng2017tgfbigenemutation pages 1-2)
References
(kheir2019mutationupdatetgfbi pages 1-2): Valeria Kheir, Vianney Cortés‐González, Juan C. Zenteno, and Daniel F. Schorderet. Mutation update: tgfbi pathogenic and likely pathogenic variants in corneal dystrophies. Human Mutation, 40:675-693, Mar 2019. URL: https://doi.org/10.1002/humu.23737, doi:10.1002/humu.23737. This article has 47 citations and is from a domain leading peer-reviewed journal.
(chang2023minireviewclinicalfeatures pages 1-3): Myung Soo Chang, Ikhyun Jun, and Eung Kweon Kim. Mini-review: clinical features and management of granular corneal dystrophy type 2. Korean Journal of Ophthalmology, 37:340-347, Aug 2023. URL: https://doi.org/10.3341/kjo.2023.0032, doi:10.3341/kjo.2023.0032. This article has 7 citations.
(chang2023minireviewclinicalfeatures pages 3-5): Myung Soo Chang, Ikhyun Jun, and Eung Kweon Kim. Mini-review: clinical features and management of granular corneal dystrophy type 2. Korean Journal of Ophthalmology, 37:340-347, Aug 2023. URL: https://doi.org/10.3341/kjo.2023.0032, doi:10.3341/kjo.2023.0032. This article has 7 citations.
(ashena2023managementofstromal pages 8-9): Zahra Ashena, Magdalena Niestrata, and Shokufeh Tavassoli. Management of stromal corneal dystrophies; review of the literature with a focus on phototherapeutic keratectomy and keratoplasty. Vision, 7:22, Mar 2023. URL: https://doi.org/10.3390/vision7010022, doi:10.3390/vision7010022. This article has 19 citations and is from a peer-reviewed journal.
(zhu2023variantlandscapeof pages 1-2): Di Zhu, Junwen Wang, Yingwei Wang, Yi Jiang, Shi-qiang Li, Xueshan Xiao, Panfeng Wang, and Qingjiong Zhang. Variant landscape of 15 genes involved in corneal dystrophies: report of 30 families and comprehensive analysis of the literature. International Journal of Molecular Sciences, 24:5012, Mar 2023. URL: https://doi.org/10.3390/ijms24055012, doi:10.3390/ijms24055012. This article has 4 citations.
(mdUnknownyearnomenclatureréviséedu pages 11-15): JSW MD, CJR MD, and MD Berthold Seitz. Nomenclature révisée du comité international pour la classification des dystrophies cornéennes (ic3d)–édition 3. Unknown journal, Unknown year.
(mdUnknownyearnomenclatureréviséedu pages 8-11): JSW MD, CJR MD, and MD Berthold Seitz. Nomenclature révisée du comité international pour la classification des dystrophies cornéennes (ic3d)–édition 3. Unknown journal, Unknown year.
(sciriha2024geneticvariantsina pages 58-61): GMG Sciriha. Genetic variants in corneal dystrophy genes: a maltese cohort study: inhibition of tgfbi as a treatment modality. Unknown journal, 2024.
(kheir2019mutationupdatetgfbi pages 2-3): Valeria Kheir, Vianney Cortés‐González, Juan C. Zenteno, and Daniel F. Schorderet. Mutation update: tgfbi pathogenic and likely pathogenic variants in corneal dystrophies. Human Mutation, 40:675-693, Mar 2019. URL: https://doi.org/10.1002/humu.23737, doi:10.1002/humu.23737. This article has 47 citations and is from a domain leading peer-reviewed journal.
(ashena2023managementofstromal pages 13-15): Zahra Ashena, Magdalena Niestrata, and Shokufeh Tavassoli. Management of stromal corneal dystrophies; review of the literature with a focus on phototherapeutic keratectomy and keratoplasty. Vision, 7:22, Mar 2023. URL: https://doi.org/10.3390/vision7010022, doi:10.3390/vision7010022. This article has 19 citations and is from a peer-reviewed journal.
(sciriha2024geneticvariantsinb pages 78-82): GMG Sciriha. Genetic variants in corneal dystrophy genes: a maltese cohort study: inhibition of tgfbi as a treatment modality. Unknown journal, 2024.
(cho2025geneticepidemiologyof pages 1-2): Eun Hye Cho, Myoungkeun Lee, Chang-Seok Ki, Chang Ahn Seol, and Mi-Ae Jang. Genetic epidemiology of epithelial-stromal tgfbi dystrophies in a large korean population. Scientific Reports, Jul 2025. URL: https://doi.org/10.1038/s41598-025-08189-7, doi:10.1038/s41598-025-08189-7. This article has 1 citations and is from a peer-reviewed journal.
(zeng2019multiplephototherapeutickeratectomy pages 1-3): Li Zeng, Jing Zhao, Yingjun Chen, Jianmin Shang, Aruma Aruma, and Xingtao Zhou. Multiple phototherapeutic keratectomy treatments in a chinese pedigree with corneal dystrophy and an r124l mutation: a 20-year observational study. BMC Ophthalmology, Aug 2019. URL: https://doi.org/10.1186/s12886-019-1167-1, doi:10.1186/s12886-019-1167-1. This article has 6 citations and is from a peer-reviewed journal.
(sciriha2025transcriptomeanalysisof pages 1-3): Gabriella Guo Sciriha, Josef Borg, Janet Sultana, and Joseph Borg. Transcriptome analysis of tgfbi knockdown vs normal corneal epithelial cells: implications for tgfbi corneal dystrophy treatment. Biochemical genetics, Jul 2025. URL: https://doi.org/10.1007/s10528-025-11191-3, doi:10.1007/s10528-025-11191-3. This article has 0 citations and is from a peer-reviewed journal.
(zeng2017tgfbigenemutation pages 1-2): Li Zeng, Jing Zhao, Yingjun Chen, Feng Zhao, Meiyan Li, Connie Chao-Shern, Tara Moore, John Marshall, and Xingtao Zhou. Tgfbi gene mutation analysis of clinically diagnosed granular corneal dystrophy patients prior to ptk: a pilot study from eastern china. Scientific Reports, Apr 2017. URL: https://doi.org/10.1038/s41598-017-00716-5, doi:10.1038/s41598-017-00716-5. This article has 8 citations and is from a peer-reviewed journal.
(sciriha2024geneticvariantsina pages 78-82): GMG Sciriha. Genetic variants in corneal dystrophy genes: a maltese cohort study: inhibition of tgfbi as a treatment modality. Unknown journal, 2024.
(NCT02746055 chunk 1): Study of the Prevalence of TGFBI Corneal Dystrophies. Avellino Labs USA, Inc.. 2016. ClinicalTrials.gov Identifier: NCT02746055
(ashena2023managementofstromal pages 1-2): Zahra Ashena, Magdalena Niestrata, and Shokufeh Tavassoli. Management of stromal corneal dystrophies; review of the literature with a focus on phototherapeutic keratectomy and keratoplasty. Vision, 7:22, Mar 2023. URL: https://doi.org/10.3390/vision7010022, doi:10.3390/vision7010022. This article has 19 citations and is from a peer-reviewed journal.
(ashena2023managementofstromal pages 21-22): Zahra Ashena, Magdalena Niestrata, and Shokufeh Tavassoli. Management of stromal corneal dystrophies; review of the literature with a focus on phototherapeutic keratectomy and keratoplasty. Vision, 7:22, Mar 2023. URL: https://doi.org/10.3390/vision7010022, doi:10.3390/vision7010022. This article has 19 citations and is from a peer-reviewed journal.
(ashena2023managementofstromal pages 19-21): Zahra Ashena, Magdalena Niestrata, and Shokufeh Tavassoli. Management of stromal corneal dystrophies; review of the literature with a focus on phototherapeutic keratectomy and keratoplasty. Vision, 7:22, Mar 2023. URL: https://doi.org/10.3390/vision7010022, doi:10.3390/vision7010022. This article has 19 citations and is from a peer-reviewed journal.
(ashena2023managementofstromal pages 11-12): Zahra Ashena, Magdalena Niestrata, and Shokufeh Tavassoli. Management of stromal corneal dystrophies; review of the literature with a focus on phototherapeutic keratectomy and keratoplasty. Vision, 7:22, Mar 2023. URL: https://doi.org/10.3390/vision7010022, doi:10.3390/vision7010022. This article has 19 citations and is from a peer-reviewed journal.
(chang2023minireviewclinicalfeatures pages 5-6): Myung Soo Chang, Ikhyun Jun, and Eung Kweon Kim. Mini-review: clinical features and management of granular corneal dystrophy type 2. Korean Journal of Ophthalmology, 37:340-347, Aug 2023. URL: https://doi.org/10.3341/kjo.2023.0032, doi:10.3341/kjo.2023.0032. This article has 7 citations.
(ashena2023managementofstromal pages 5-7): Zahra Ashena, Magdalena Niestrata, and Shokufeh Tavassoli. Management of stromal corneal dystrophies; review of the literature with a focus on phototherapeutic keratectomy and keratoplasty. Vision, 7:22, Mar 2023. URL: https://doi.org/10.3390/vision7010022, doi:10.3390/vision7010022. This article has 19 citations and is from a peer-reviewed journal.
(sciriha2024geneticvariantsin pages 78-82): GMG Sciriha. Genetic variants in corneal dystrophy genes: a maltese cohort study: inhibition of tgfbi as a treatment modality. Unknown journal, 2024.
(chang2023minireviewclinicalfeatures pages 6-8): Myung Soo Chang, Ikhyun Jun, and Eung Kweon Kim. Mini-review: clinical features and management of granular corneal dystrophy type 2. Korean Journal of Ophthalmology, 37:340-347, Aug 2023. URL: https://doi.org/10.3341/kjo.2023.0032, doi:10.3341/kjo.2023.0032. This article has 7 citations.